Blood · 2006 · 65 citations · 26 references
Life SciencesMolecular BiologyOncologyApoptosisCell SignalingSignal TransductionApoptosis In CancerApoptosis RegulationApoptotic SignalingBcl-2 Family ProteinsMultiple MyelomaApoptosis Signaling In CancerDeath Ligand SignalingMcl-1 FunctionMyeloma PathogenesisTrail ReceptorsTrail-mediated Apoptosis
We evaluated the ability of 2 human mAbs directed against TRAILR1 (HGS-ETR1) and TRAILR2 (HGS-ETR2) to kill human myeloma cells. HGS-ETR1 and HGS-ETR2 mAbs killed 15 and 9 human myeloma cell lines (HMCLs; n = 22), respectively. IL-6, the major survival and growth factor for these HMCLs, did not prevent their killing. Killing induced by either HGS-ETR1 or HGS-ETR2 was correlated with the cleavage of Mcl-1L, a major molecule for myeloma survival. Mcl-1L cleavage and anti-TRAILR HMCL killing were dependent on caspase activation. Kinetic studies showed that Mcl-1L cleavage occurred very early (less than 1 hour) and became drastic once caspase 3 was activated. Our data showed that both the extrinsic (caspase 8, Bid) and the intrinsic (caspase 9) pathways are activated by anti-TRAIL mAb. Finally, we showed that the HGS-ETR1 and, to a lesser extent, the HGS-ETR2 mAbs were able to induce the killing of primary myeloma cells. Of note, HGS-ETR1 mAb was able to induce the death of medullary and extramedullary myeloma cells collected from patients at relapse. Taken together, our data clearly encourage clinical trials of anti-TRAILR1 mAb in multiple myeloma, especially for patients whose disease is in relapse, at the time of drug resistance.
26
Genetics and Cytogenetics of Multiple Myeloma
Rafaël Fonseca, Bart Barlogie, Régis Bataille et al. · Cancer Research · 2004 · 686 citations
Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells
Joseph T. Opferman, Hiromi Iwasaki, Christy C. Ong et al. · Science · 2005 · 565 citations